



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/410959/2024

European Medicines Agency decision P/0316/2024

of 13 September 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215), (EMEA-003510-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0316/2024

of 13 September 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215), (EMA-003510-PIP01-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Astria Therapeutics, Inc. on 11 September 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Astria Therapeutics, Inc., 75 State Street, Suite 1400, MA 02109 – Boston, USA.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/228230/2024
Amsterdam, 26 July 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003510-PIP01-23

Scope of the application

Active substance(s):

Recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of hereditary angioedema

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Astria Therapeutics, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Astria Therapeutics, Inc. submitted for agreement to the European Medicines Agency on 11 September 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 16 October 2023.

Supplementary information was provided by the applicant on 29 April 2024. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of hereditary angioedema

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of hereditary angioedema

2.1.1. Indication(s) targeted by the PIP

Routine prevention of recurrent attacks of hereditary angioedema

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 (STAR-0215-PIP Quality) Development of a lower strength of solution for injection appropriate for the paediatric population from 2 years to less than 12 years of age
Non-clinical studies	Not applicable
Clinical studies	Study 2 (STAR-0215-301) Randomised, double-blind, placebo-controlled trial to evaluate efficacy, safety and pharmacokinetics (PK) of recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215) for prevention of angioedema attacks in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema

	Study 3 (STAR-0215-303) Open-label trial to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215) in children from 2 years to less than 12 years of age with hereditary angioedema
Modelling and simulation analyses	Study 4 (STAR-0215-PIP M&S-1) Population PK (popPK) model to inform dose selection and support extrapolation of efficacy to the target paediatric population
Other studies	Study 5 (STAR-0215-PIP Extrapolation-1) Analysis of in-house data to support the use of STAR-0215 in the paediatric population from 2 years to less than 18 years of age with hereditary angioedema

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2032
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.